NASDAQ:IMMU - Immunomedics Stock Price, Price Target & More

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

Immunomedics (NASDAQ:IMMU) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.06. The biopharmaceutical company had revenue of $0.50 million for the quarter, compared to analyst estimates of $4.27 million. The firm's quarterly revenue was down 61.5% on a year-over-year basis. View Immunomedics' Earnings History.

2 brokers have issued twelve-month target prices for Immunomedics' stock. Their forecasts range from $15.00 to $27.00. On average, they anticipate Immunomedics' share price to reach $21.00 in the next year. View Analyst Ratings for Immunomedics.

Immunomedics saw a increase in short interest in April. As of April 30th, there was short interest totalling 28,420,435 shares, an increase of 0.1% from the April 13th total of 28,384,688 shares. Based on an average trading volume of 1,792,307 shares, the short-interest ratio is presently 15.9 days. Currently, 19.2% of the shares of the stock are sold short.

Some companies that are related to Immunomedics include Ipsen (IPSEY), Neogen (NEOG), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), New England Nuclear (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), Vermillion (VRML) and Akers Biosciences (AKER).

Press coverage about IMMU stock has trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Immunomedics earned a media sentiment score of 0.16 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.65 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Immunomedics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.45%), Acuta Capital Partners LLC (3.50%), Palo Alto Investors LP (2.87%), Victory Capital Management Inc. (1.13%), Northern Trust Corp (0.76%) and Nexthera Capital LP (0.65%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark, Mary E Paetzold and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

IMMU stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, JPMorgan Chase & Co., Lyon Street Capital LLC, UBS Group AG, Jane Street Group LLC, Iguana Healthcare Management LLC, Highland Capital Management LP and BlackRock Inc.. Company insiders that have sold Immunomedics company stock in the last year include Brian A Markison, Cynthia L Goldenberg and David M Goldenberg. View Insider Buying and Selling for Immunomedics.

IMMU stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Nexthera Capital LP, Massachusetts Financial Services Co. MA, Rock Springs Capital Management LP, Sphera Funds Management LTD., University of Notre Dame DU Lac, Royal Bank of Canada and DekaBank Deutsche Girozentrale. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IMMU stock can currently be purchased for approximately $21.15.

Immunomedics has a market capitalization of $3.51 billion and generates $3.09 million in revenue each year. The biopharmaceutical company earns $-153,200,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Immunomedics employs 138 workers across the globe.

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]